The year 2019 has been successful for Pliva and it will be a record one as the company expects revenues in the amount of five billion kuna, Mihael Furjan, management board chair of that pharmaceutical company, told reporters on Wednesday.

“We can be satisfied with this year as our revenues are almost two billion higher than last year, when they totalled slightly more than four billion kuna. This is a result of sales growth as well as of one-off revenues because we have sold some of our development projects,” said Furjan.

He stressed that the higher revenues would result in higher profits.

In 2020 Pliva expects moderate business growth as well as a moderate increase in demand in foreign markets, unlike Croatia, where no major changes are expected considering financial problems in the health sector.

The expectation of an increase in demand is based on a growing demand for drugs globally, and Pliva Hrvatska is known as the member of the Teva Group that launches the most new products of all 60 Teva locations globally, said Furjan.

“Every year we launch a dozen new products and in that regard Zagreb is Teva’s leading location. This year we have produced a large quantity of various products. We have all global regulatory permits and we have passed all inspections this year, without any irregularity found,” he said.

Of the export markets, the United States continues to be Pliva’s main market, where it earns around one billion kuna in revenues. Pliva also produces for many other markets and Japan is a new one.

Furjan said that the company employed 2,350 workers and that their number would grow depending on demand growth, stressing that the pharmaceutical industry was one of the strongest industries in Croatia, with the highest export growth.

(€1= HRK 7.4)